Papers of the Week

Signaling through calcitonin gene-related peptide (CGRP) receptors is associated with pain, migraine, and energy expenditure. Small molecule and monoclonal antibody CGRP receptor antagonists that block endogenous CGRP action are in clinical use as anti-migraine therapies. By comparison, the potential utility of peptide antagonists has received less attention due to suboptimal pharmacokinetic properties. Lipidation is an established strategy to increase peptide half-life . This study aimed to explore the feasibility of developing lipidated CGRP peptide antagonists that retain receptor antagonist activity and attenuate endogenous CGRP action . CGRP peptide analogues based on the archetypal CGRP receptor antagonist, CGRP, were palmitoylated at the N-terminus, position 24, and near the C-terminus at position 35. The antagonist activities of the lipidated peptide analogues were tested using transfected Cos-7 cells expressing either the human or mouse CGRP receptor, amylin subtype 1 (AMY) receptor, adrenomedullin (AM) receptors, or calcitonin receptor. Antagonist activities were also evaluated in SK-N-MC cells that endogenously express the human CGRP receptor. Lipidated peptides were then tested for their ability to antagonize endogenous CGRP action using a capsaicin-induced dermal vasodilation (CIDV) model in C57/BL6J mice. All lipidated peptides except for the C-terminally modified analogue retained potent antagonist activity compared to CGRP towards the CGRP receptor. The lipidated peptides also retained, and sometimes gained, antagonist activities at AMY, AM and AM receptors. Several lipidated peptides produced robust inhibition of CIDV in mice. This study demonstrates that selected lipidated peptide antagonists based on αCGRP retain potent antagonist activity at the CGRP receptor and are capable of inhibition of endogenous CGRP action . These findings suggest that lipidation can be applied to peptide antagonists, such as αCGRP and are a potential strategy for antagonizing CGRP action.